Author

A. Trivette

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 6 Assay:proteomics· 5 Research Focus:host-pathogen & immune response· 4 Research Focus:cell type annotation· 2 Research Focus:cell-cell communication· 1 Assay:CITE-seq· 1 Research Focus:differential expression· 1

Frequent Co-Authors

E. Binshtein· 6 shared J. E. Crowe· 6 shared L. Myers· 5 shared R. H. Carnahan· 5 shared E. C. Chen· 4 shared J. X. Reidy· 4 shared M. S. Diamond· 4 shared N. Suryadevara· 4 shared

Activity by Year

2020-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

E. Binshtein

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies

T. B. Engdahl, E. Binshtein, R. L. Brocato, N. A. A. Kuzmina, L. M. Principe, S. A. Kwilas, R. K. Kim, N. S. Chapman, M. S. Porter, P. Guardado-Calvo, F. A. Rey, L. S. Handal, S. M. Diaz, I. A. Zagol-Ikapitte, J. X. Reidy, , J. E. Crowe

This study maps antigenic sites and characterizes neutralizing antibodies against hantaviruses, identifying mechanisms and cross-protective potential for vaccine development.

bioRxiv · Jul 19, 2022Immunology

Systematic analysis of human antibody response to ebolavirus glycoprotein reveals high prevalence of neutralizing public clonotypes

E. C. Chen, P. Gilchuk, S. J. Zost, P. A. Ilinykh, E. Binshtein, K. Huang, L. Myers, S. Bonissone, S. Day, C. R. Kona, A. Trivette, J. X. Reidy, R. E. Sutton, C. Gainza, S. Monroig, , J. E. Crowe

The paper analyzes the human antibody response to ebolavirus glycoprotein, identifying public clonotypes with neutralizing activity and implications for vaccine design.

bioRxiv · Jan 12, 2022 · PreprintImmunology

An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer

N. Suryadevara, A. Shiakolas, L. VanBlargan, E. Binshtein, R. Chen, J. B. Case, K. Kramer, E. Armstrong, L. Myers, A. Trivette, C. Gainza, R. Nargi, C. Selverian, E. Davidson, B. Doranz, , J. E. Crowe

The paper identifies a rare antibody that targets the SARS-CoV-2 spike trimer interface, disrupting viral entry and providing protection in mice.

bioRxiv · Jan 12, 2022Immunology

Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals

E. C. Chen, P. Gilchuk, S. J. Zost, N. Suryadevara, E. S. Winkler, C. R. Cabel, E. Binshtein, R. E. Sutton, J. L. Rodriguez, S. Day, L. Myers, A. Trivette, J. K. Williams, E. Davidson, S. Li, , J. E. Crowe

The paper identifies public antibody clonotypes in SARS-CoV-2 convalescents and vaccinated individuals, revealing common epitope recognition and potential vaccine efficacy mechanisms.

bioRxiv · May 2, 2021Immunology

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

S. J. Zost, P. Gilchuk, J. B. Case, E. Binshtein, R. E. Chen, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, L. E. Williamson, E. C. Chen, T. Jones, S. Day, L. Myers, , J. E. Crowe

The paper identifies potent neutralizing antibodies against SARS-CoV-2 that block receptor binding and protect animals, providing insights for vaccine and therapy development.

bioRxiv · May 22, 2020Immunology

Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein

S. J. Zost, P. Gilchuk, R. Chen, J. B. Case, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, E. C. Chen, E. Binshtein, S. Shrihari, M. A. Ostrowski, H. Y. Chu, J. E. Didier, , J. E. Crowe

This study isolates and profiles human monoclonal antibodies against SARS-CoV-2 spike protein, identifying neutralizing antibodies targeting the receptor-binding domain.

bioRxiv · May 12, 2020Immunology